J Gen Virol Try IJSEM Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ring, C. J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ring, C. J. A.
Agricola
Right arrow Articles by Ring, C. J. A.
Journal of General Virology (2002), 83, 491-502.
© 2002 Society for General Microbiology

Review Article

Cytolytic viruses as potential anti-cancer agents

Christopher J. A. Ring1

Gene Interference, Glaxo SmithKline Research & Development, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK1

Author for correspondence: Christopher Ring. Fax +44 1438 768097. e-mail cjr48991{at}gsk.com

The resistance of cancers to conventional therapies has inspired the search for novel strategies. One such approach, namely gene therapy, is based upon the introduction of genes such as those encoding suicide proteins, tumour suppressor proteins or cytokines into tumour cells by means of a genetic vector. The efficiency with which viruses transfer their genes from one host cell to another has led to the widespread use of viruses as genetic vectors. For safety reasons, such virus vectors are generally replication-defective but, unfortunately, this has limited the efficacy of treatment by restricting the number of cells to which the therapeutic gene is delivered. For this reason, the use of replication-competent viruses has been proposed, since virus replication would be expected to lead to amplification and spread of the therapeutic genes in vivo. The replication of many viruses results in lysis of the host cells. This inherent cytotoxicity, together with the efficiency with which viruses can spread from one cell to another, has inspired the notion that replication-competent viruses could be exploited for cancer treatment. Some viruses have been shown to replicate more efficiently in transformed cells but it is unlikely that such examples will exhibit a high enough degree of tumour selectivity, and hence safety, for the treatment of patients. Our increasing knowledge of the pathogenesis of virus disease and the ability to manipulate specific regions of viral genomes have allowed the construction of viruses that are attenuated in normal cells but retain their ability to lyse tumour cells. Such manipulations have included modifying the ability of viruses to bind to, or replicate in, particular cell types, while others have involved the construction of replication-competent viruses encoding suicide proteins or cytokines. Naturally occurring or genetically engineered oncolytic viruses based upon adenovirus, herpes simplex virus, Newcastle disease virus, poliovirus, vesicular stomatitis virus, weasles virus and reovirus have been described. The results of animal studies are encouraging and a number of viruses are now being evaluated in clinical trials.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
H. Toyoda, J. Yin, S. Mueller, E. Wimmer, and J. Cello
Oncolytic Treatment and Cure of Neuroblastoma by a Novel Attenuated Poliovirus in a Novel Poliovirus-Susceptible Animal Model
Cancer Res., March 15, 2007; 67(6): 2857 - 2864.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. Zhang, G. Chen, L. Peng, X. Wang, Y. Yang, C. Liu, W. Shi, C. Su, H. Wu, X. Liu, et al.
Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Clin. Cancer Res., November 1, 2006; 12(21): 6523 - 6531.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Y. Gao, P. Whitaker-Dowling, S. C. Watkins, J. A. Griffin, and I. Bergman
Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line.
J. Virol., September 1, 2006; 80(17): 8603 - 8612.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. R. Simpson, Z. Han, B. Liu, Y. Wang, G. Campbell, and R. S. Coffin
Combination of a Fusogenic Glycoprotein, Prodrug Activation, and Oncolytic Herpes Simplex Virus for Enhanced Local Tumor Control.
Cancer Res., May 1, 2006; 66(9): 4835 - 4842.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. Wurdinger, M. H. Verheije, K. Broen, B. J. Bosch, B. J. Haijema, C. A. M. de Haan, V. W. van Beusechem, W. R. Gerritsen, and P. J. M. Rottier
Soluble Receptor-Mediated Targeting of Mouse Hepatitis Coronavirus to the Human Epidermal Growth Factor Receptor
J. Virol., December 15, 2005; 79(24): 15314 - 15322.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. Springfeld, V. von Messling, C. A. Tidona, G. Darai, and R. Cattaneo
Envelope Targeting: Hemagglutinin Attachment Specificity Rather than Fusion Protein Cleavage-Activation Restricts Tupaia Paramyxovirus Tropism
J. Virol., August 15, 2005; 79(16): 10155 - 10163.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Unno, Y. Shino, F. Kondo, N. Igarashi, G. Wang, R. Shimura, T. Yamaguchi, T. Asano, H. Saisho, S. Sekiya, et al.
Oncolytic Viral Therapy for Cervical and Ovarian Cancer Cells by Sindbis Virus AR339 Strain
Clin. Cancer Res., June 15, 2005; 11(12): 4553 - 4560.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. A. I. Abou El Hassan, I. van der Meulen-Muileman, S. Abbas, and F. A. E. Kruyt
Conditionally Replicating Adenoviruses Kill Tumor Cells via a Basic Apoptotic Machinery-Independent Mechanism That Resembles Necrosis-Like Programmed Cell Death
J. Virol., November 15, 2004; 78(22): 12243 - 12251.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Geoerger, G. Vassal, P. Opolon, C. M. F. Dirven, J. Morizet, L. Laudani, J. Grill, G. Giaccone, W. P. Vandertop, W. R. Gerritsen, et al.
Oncolytic Activity of p53-Expressing Conditionally Replicative Adenovirus Ad{Delta}24-p53 against Human Malignant Glioma
Cancer Res., August 15, 2004; 64(16): 5753 - 5759.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir
Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer
Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Zhang, M. Nie, J. Sham, C. Su, H. Xue, D. Chua, W. Wang, Z. Cui, Y. Liu, C. Liu, et al.
Effective Gene-Viral Therapy for Telomerase-Positive Cancers by Selective Replicative-Competent Adenovirus Combining with Endostatin Gene
Cancer Res., August 1, 2004; 64(15): 5390 - 5397.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Wirth, L. Zender, B. Schulte, B. Mundt, R. Plentz, K. L. Rudolph, M. Manns, S. Kubicka, and F. Kuhnel
A Telomerase-dependent Conditionally Replicating Adenovirus for Selective Treatment of Cancer
Cancer Res., June 15, 2003; 63(12): 3181 - 3188.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 2002 by the Society for General Microbiology.